Get the Stockscreener App
2.525
1.41%
0.035
Ac Immune Sa stock is traded at $2.525, with a volume of 69,395.
It is up +1.41% in the last 24 hours and up +14.77% over the past month.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
See More
Previous Close:
$2.49
Open:
$2.49
24h Volume:
69,395
Relative Volume:
0.27
Market Cap:
$251.05M
Revenue:
$4.60M
Net Income/Loss:
$-82.31M
P/E Ratio:
-3.0785
EPS:
-0.8202
Net Cash Flow:
$-87.79M
1W Performance:
+10.75%
1M Performance:
+14.77%
6M Performance:
-13.23%
1Y Performance:
+18.54%
1-Day Range:
$2.4698
$2.545
1-Week Range:
$2.3489
$2.70
52-Week Range:
$2.03
$4.00
Ac Immune Sa Stock (ACIU) Company Profile
Compare ACIU vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
2.525 | 247.57M | 4.60M | -82.31M | -87.79M | -0.8202 |
VRTX
Vertex Pharmaceuticals Inc
|
516.25 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.82 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.77 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
215.15 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.23 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-31-24 | Initiated | BTIG Research | Buy |
| Feb-01-19 | Downgrade | UBS | Buy → Neutral |
| Jan-04-19 | Initiated | UBS | Buy |
| Apr-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-23-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-18-16 | Initiated | Credit Suisse | Outperform |
| Oct-18-16 | Initiated | Jefferies | Buy |
| Oct-18-16 | Initiated | Leerink Partners | Outperform |
View All
Ac Immune Sa Stock (ACIU) Latest News
AC Immune takes Parkinson's vaccine into US trials as Phase II data near - AllSci
ACIU Looks 33.6% Undervalued on GF Value™ Despite Financial Chal - GuruFocus
AC Immune receives FDA fast track status for parkinson’s drug By Investing.com - Investing.com Nigeria
AC Immune Wins FDA Fast Track for ACI-7104 in Early Parkinson’s Disease - TipRanks
AC Immune receives FDA fast track status for parkinson’s drug - Investing.com
AC Immune (NASDAQ: ACIU) gains FDA Fast Track, IND clearance for Parkinson’s drug ACI-7104 - Stock Titan
AC Immune’s Parkinson’s Candidate Shows 100% Responder Rate - Stock Titan
AC Immune (ACIU) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
AC Immune SA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - simplywall.st
Analyst Reiterates Buy on AC Immune as 2H26 Catalysts Approach; Price Target Maintained at $12 - TipRanks
AC Immune (NasdaqGM:ACIU) Stock Price Shrugs Off Surprise Quarterly Profit - Sahm
ACIU Reiterated by BTIG -- Maintains Price Target at $8.00 - GuruFocus
AC Immune SA reports results for the quarter ended June 30Earnings Summary - TradingView
AC Immune Files First-Half 2026 Results and Corporate Update on Form 6-K - TipRanks
AC Immune: Q2 Earnings Snapshot - Barchart.com
AC Immune First Half 2026 Financial and Corporate Update - The Manila Times
Partner milestones lift AC Immune (NASDAQ: ACIU) cash and cut loss - stocktitan.net
AC Immune’s Parkinson’s Trial Gets a $4 Million Grant - Stock Titan
AC Immune (ACIU) Drops 6.12% as Support at $2.12 Comes into FocusSynthetic Short - dars.gov.et
ACIU Q2'26 Earnings: EPS estimate is 0.12 USD - TradingView
AC Immune SA (ACIU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AC Immune SA (ACIU) Institutional Confidence - TradingKey
AC Immune SA (ACIU) Cash Flow - TradingKey
TradingKey - TradingKey
AC Immune SA (ACIU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ACIU|AC Immune SA|Price:2.230|Chg%:-0.010 - TradingKey
AC Immune SA Revenue Breakdown – TRADEGATE:IMR - TradingView
AC Immune SA (ACIU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ACIU Q2'26 Earnings: revenue estimate is 34.08M USD - TradingView
AC Immune Q1 2026 Earnings: Narrower Loss and Positive Surprise Highlight ProgressProduct Revenue Analysis - dars.gov.et
AC Immune (ACIU) Posts Modest Gain, Holds Above Key SupportDay Trade Opportunities - dars.gov.et
AC Immune SA Q1 2026 Earnings: EPS Beat by 3.29% as Pre-Revenue Biotech Navigates Pipeline ProgressProfit Recovery Report - dars.gov.et
AC Immune Q1 2026 Earnings: Narrowed Loss Per Share Exceeds Expectations, Stock RisesAnalyst Coverage Count - dars.gov.et
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026 - The Manila Times
AC Immune brings three neurodegeneration studies to AAIC 2026 - Stock Titan
AC Immune to present new neurodegenerative dise... - Pluang
ACIU Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Stock ReactionEarnings Recovery Stocks - po-news-eg.net
AC Immune: Holding Into A Make-Or-Break H2 2026 Readout (NASDAQ:ACIU) - Seeking Alpha
H.C. Wainwright reiterates AC Immune stock rating on trial data By Investing.com - Investing.com Australia
H.C. Wainwright reiterates AC Immune stock rating on trial data - Investing.com
AC Immune (ACIU) Slides 6.93% as Biotech Pressure Mounts – Key Support in FocusCollar Trade - dars.gov.et
Price to earnings forward of AC Immune SA – DUS:IMR - TradingView
Price to sales forward of AC Immune SA – NASDAQ:ACIU - TradingView
AC Immune Unveils 12-Month Interim Data from ACI-24 Alzheimer’s Trial and Expands Takeda-Backed Program - TipRanks
Takeda-backed AC Immune (NASDAQ: ACIU) reports ACI-24 Alzheimer’s trial update - Stock Titan
ACIU: Promising Interim Results from AC Immune's Alzheimer's Stu - GuruFocus
AC Immune reports interim trial data for Alzheimer’s drug ACI-24 - Investing.com Australia
AC Immune Reports Interim 12-Month ABATE Data for ACI-24 in Prodromal Alzheimer’s Disease - Quiver Quantitative
AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease - GlobeNewswire
AC Immune Q1 2026 Earnings: Narrowing Losses and Positive Pipeline MomentumProfit Cycle Analysis - dars.gov.et
Enterprise value to EBITDA forward of AC Immune SA – NASDAQ:ACIU - TradingView
Ac Immune Sa Stock (ACIU) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):